Literature DB >> 23117849

Clinical outcome after a totally implantable venous access port-related infection in cancer patients: a prospective study and review of the literature.

David Lebeaux1, Béatrice Larroque, Justine Gellen-Dautremer, Véronique Leflon-Guibout, Chantal Dreyer, Suzanne Bialek, Antoine Froissart, Olivia Hentic, Catherine Tessier, Raymond Ruimy, Anne-Laure Pelletier, Bruno Crestani, Michel Fournier, Thomas Papo, Béatrix Barry, Virginie Zarrouk, Bruno Fantin.   

Abstract

Morbidity and mortality after a totally implantable venous access port (TIVAP)-related infection in oncology patients have rarely been studied. We conducted this study to assess the incidence and factors associated with the following outcome endpoints: severe sepsis or septic shock at presentation, cancellation of antineoplastic chemotherapy, and mortality at week 12. We conducted a prospective single-center observational study including all adult patients with solid cancer who experienced a TIVAP-related infection between February 1, 2009, and October 31, 2010. Patients were prospectively followed for 12 weeks. Among 1728 patients receiving antineoplastic chemotherapy during the inclusion time, 72 had an episode of TIVAP-related infection (4.2%) and were included in the study (median age, 60 yr; range, 28-85 yr). The incidence of complications was 18% for severe sepsis or septic shock (13/72 patients), 30% for definitive cancellation of antineoplastic chemotherapy (14/46 patients who still had active treatment), and 46% for death at week 12 (33/72 patients). Factors associated with severe sepsis or septic shock were an elevated C-reactive protein (CRP) level and an infection caused by Candida species; 4 of the 13 severe episodes (31%) were due to coagulase-negative staphylococci (CoNS). Factors associated with death at week 12 were a low median Karnofsky score, an elevated Charlson comorbidity index, the metastatic evolution of cancer, palliative care, and an elevated CRP level at presentation. Hematogenous complications (that is, infective endocarditis, septic thrombophlebitis, septic pulmonary emboli, spondylodiscitis, septic arthritis, or organ abscesses) were found in 8 patients (11%). In conclusion, patients' overall condition (comorbidities and autonomy) and elevated CRP level were associated with an unfavorable clinical outcome after a TIVAP-related infection. Candida species and CoNS were responsible for severe sepsis or septic shock.

Entities:  

Mesh:

Year:  2012        PMID: 23117849     DOI: 10.1097/MD.0b013e318275ffe1

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  13 in total

1.  Totally implantable venous access ports: a prospective long-term study of early and late complications in adult patients with cancer.

Authors:  Eric Voog; Loïc Campion; Pauline du Rusquec; Hugues Bourgeois; Julien Domont; Fabrice Denis; Eric Emmanuel; Olivier Dupuis; Gérard Ganem; Cedrik Lafont; Katell Le Du; Elena Pavluc; Yohan Pointreau; Sophie Roche; Laurence Juhel-Voog; Marie Zinger; Philippe Solal-Celigny
Journal:  Support Care Cancer       Date:  2017-07-29       Impact factor: 3.603

2.  Role of Lock Therapy for Long-Term Catheter-Related Infections by Multidrug-Resistant Bacteria.

Authors:  Maristela P Freire; Ligia C Pierrotti; Antonio E Zerati; Luciana Benites; Joaquim Mauricio da Motta-Leal Filho; Karim Y Ibrahim; Pedro H Araujo; Edson Abdala
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

3.  Wound Closure After Port Implantation-A Randomized Controlled Trial Comparing Tissue Adhesive and Intracutaneous Suturing.

Authors:  Saskia Witting; Maja Ingwersen; Thomas Lehmann; René Aschenbach; Niklas Eckardt; Jürgen Zanow; René Fahrner; Stephan Lotze; Reinhard Friedel; Mark Lenz; Claudia Schmidt; Diana Miguel; Laine Ludriksone; Ulf Teichgräber
Journal:  Dtsch Arztebl Int       Date:  2021-11-05       Impact factor: 8.251

4.  Long-term outcomes of totally implantable venous access devices.

Authors:  Yi-Chia Wang; Pei-Lin Lin; Wei-Han Chou; Chih-Peng Lin; Chi-Hsiang Huang
Journal:  Support Care Cancer       Date:  2017-02-09       Impact factor: 3.603

5.  Comparative Analysis of Bacterial Community Composition and Structure in Clinically Symptomatic and Asymptomatic Central Venous Catheters.

Authors:  Franziska A Stressmann; Elodie Couve-Deacon; Delphine Chainier; Ashwini Chauhan; Aimee Wessel; Sylvaine Durand-Fontanier; Marie-Christine Escande; Irène Kriegel; Bruno Francois; Marie-Cécile Ploy; Christophe Beloin; Jean-Marc Ghigo
Journal:  mSphere       Date:  2017-09-27       Impact factor: 4.389

6.  Removal of totally implanted venous access ports for suspected infection in the intensive care unit: a multicenter observational study.

Authors:  Marie Lecronier; Sandrine Valade; Naike Bigé; Nicolas de Prost; Damien Roux; David Lebeaux; Eric Maury; Elie Azoulay; Alexandre Demoule; Martin Dres
Journal:  Ann Intensive Care       Date:  2018-03-27       Impact factor: 6.925

7.  Totally Implantable Venous-Access Device Infection Causing Hematogenous Prosthetic Joint Infection: A Retrospective Case Series.

Authors:  Fernanda Medina; Vanina Meyssonnier; Valérie Zeller; Beate Heym; Jean-Marc Ziza; Simon Marmor
Journal:  J Bone Jt Infect       Date:  2018-10-31

8.  Experience in totally implantable venous port catheter: Analysis of 3,000 patients in 12 years.

Authors:  Fazlı Yanık; Yekta Altemur Karamustafaoğlu; Adem Karataş; Yener Yörük
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2018-07-03       Impact factor: 0.332

9.  Incidence and risk factors of infectious complications related to implantable venous-access ports.

Authors:  Jisue Shim; Tae-Seok Seo; Myung Gyu Song; In-Ho Cha; Jun Suk Kim; Chul Won Choi; Jae Hong Seo; Sang Cheul Oh
Journal:  Korean J Radiol       Date:  2014-07-09       Impact factor: 3.500

10.  Implantable Port Devices, Complications and outcome in Pediatric Cancer, a Retrospective Study.

Authors:  H Esfahani; M Ghorbanpor; A Tanasan
Journal:  Iran J Ped Hematol Oncol       Date:  2016-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.